Company: QTIWW
Filing Date: 2025-02-05
Form Type: 424B3
Source: 0001628280-25-004061
Chunk: 13

Company: QT IMAGING HOLDINGS, INC.
Filing Date: 2025-02-05
Form: 424B3
Chunk 13
---
 size/tissue type breast imaging technology, as well as the techniques for quantifiable analysis, comparison, and training.

• Partner with strategic business and distribution channels to address U.S. market for breast imaging im-mediately and, other regions in the future, to place the QT Breast Scanner in hospitals, radiology centers, etc. and generate awareness of the benefits of the Company’s technology.

• Perform small scale manufacturing internally to the Company and partner strategically for large scale manufacturing.

• Expand the market by supporting additional DTC and DTP approaches to enable the ability to lower health care costs and increase access via personal medical imaging.

<div align='center'>7</div>

#### Table of Contents
• Provide a new social and economic opportunity for consumers to take control of some aspects of their own health care—such as imaging for minor injuries or medical conditions without needing a healthcare “gate-keeper.”

• Focus our intellectual capabilities and ethical framework to become unified in our mission to improve the quality and lower the cost of health care world-wide... “It’s about time.”

#### Additional Material Agreements

#### Canon Letter of Intent
QT Imaging has entered into a non-binding letter of intent (the “

#### Canon Letter of Intent
”), with CMSU and Canon Medical Systems Corporation (“

#### CMSC
”), a company organized and existing under the laws of Japan, pursuant to which CMSC purchased and acquired two QT Breast Scanners in the first half of 2024. The Canon Letter of Intent provided that CMSC would conduct, and pursuant to the Feasibility Study Agreement (as described below), CMSC conducted, feasibility studies on the QT Breast Scanners that it acquired, including product quality validation, development and manufacturing studies, clinical evaluation, regulatory investigation and marketing validation (the “

#### Feasibility Study
”). The Feasibility Study was completed in the second half of 2024.

The Canon Letter of Intent provided that upon successful conclusion of the Feasibility Study, we and CMSC intended to engage in a good faith discussion to develop a binding original equipment manufacturing (“

#### OEM
”) agreement with CMSC.

CMSC will also use QT Breast Scanners that it acquired to perform clinical trials towards the possibility of it pursuing the regulatory approval process in Japan.

CMSC and QT Imaging have also discussed other potential terms between them.

Feasibility Agreement with Canon Medical Systems Corporation

On March 28, 2024, we entered into a Feasibility Study Agreement (the “

#### Feasibility Study Agreement